No Data
Qianjiang Yongan Pharmaceutical (002365.SZ): The invested company is currently not producing carbon nanotubes.
On December 13, Gelonghui reported that Qianjiang Yongan Pharmaceutical (002365.SZ) stated on the investor interaction platform that its invested company, Wuhan Low-Dimensional, is currently focusing on the heating field of carbon-based materials and is not producing carbon nanotubes or any Solid State Battery related products.
Qianjiang Yongan Pharmaceutical (002365.SZ): has received an invention patent certificate.
On November 29, Gelonhui reported that qianjiang yongan pharmaceutical (002365.SZ) announced that the company recently received an invention patent certificate issued by the National Intellectual Property Administration, with the invention titled 'a method and system for removing impurities in taurine mother liquor recycling.'
Qianjiang Yongan Pharmaceutical (002365.SZ): has repurchased 1.17% of the shares.
GeLongHui, November 1st | qianjiang yongan pharmaceutical (002365.SZ) announced that as of the end of October 2024, the company has repurchased a total of 3,442,350.00 shares of the company through centralized auction, accounting for 1.17% of the total share capital of the company. The highest fill price was 7.30 yuan/share, the lowest fill price was 6.67 yuan/share, and the total fill price amount was 24.1702 million yuan (excluding transaction costs).
Yongan Pharmaceutical: Report for the third quarter of 2024
qianjiang yongan pharmaceutical (002365.SZ) released its performance for the first three quarters, with a net income of 61.8552 million yuan, a year-on-year increase of 33.23%.
Qianjiang Yongan Pharmaceutical (002365.SZ) released its third quarter report for 2024. In the first three quarters, the company achieved revenue...
Qianjiang Yongan Pharmaceutical (002365.SZ): The net income in the first three quarters was 61.8552 million yuan, a year-on-year increase of 33.23%.
Gelonghui, October 29th - Qianjiang Yongan Pharmaceutical (002365.SZ) announced its third quarter report for 2024, achieving revenue of 0.619 billion yuan in the first three quarters, a year-on-year decrease of 22.93%; net income attributable to shareholders of the listed company was 61.8552 million yuan, a year-on-year increase of 33.23%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 37.4882 million yuan, a year-on-year increase of 489.66%; basic earnings per share was 0.2105 yuan.
Benign Growth For Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) Underpins Stock's 27% Plummet
